REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf135 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Jeffrey Zhong und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Me…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Immunotherapy, Kidney Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Exelixis and Kure It Research.
Abstract (Originalsprache)
The REnal cancer consortium for Focused Investigation of Novel biomarkers and Expression (REFINE) consortium represents an important initiative in integrating clinical data with molecular sequencing in patients with advanced renal cell carcinoma (RCC) treated with immunotherapy-based approaches. By leveraging real-world evidence and genomic analysis, this consortium aims to explore putative predictive biomarkers with the potential to inform personalized treatment strategies. Findings from the REFINE database may further contribute to our understanding of disease courses of immunotherapy-based approaches for various molecular subtypes of RCC, associations of race and ethnicity with RCC treatment and outcomes with representation of patient populations underrepresented in clinical trials, and optimizing treatment sequencing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.
- Division of Oncology, Holden Comprehensive Cancer Center, Iowa City, IA 52242, United States.
- Division of Hematology-Oncology, University of Alabama O'Neal Comprehensive Cancer Center, Birmingham, AL 35233, United States.
- Hoag Family Cancer Institute, Newport Beach, CA 92663, United States.
- Division of Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
- Genitourinary Medical Oncology Program, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, United States.
ORCID-Profile: Jeffrey Zhong, Andrew Elliott, Rana R McKay, Pedro C Barata
Förderung
- Exelixis and Kure It Research
Zitieren
APA
Zhong, J., Jang, A., Abuqayas, B., Basu, A., Benjamin, D. J., Bhatlapenumarthi, V., Bilen, M. A., Buch, D., Chang, M., Chin, E., Darabi, S., Dhanikonda, N., Ghatalia, P., Grigg, C. M., Grier, A. L., Jindal, T., Jung, J., Kilari, D., Kumar, H. L. S., …, & Barata, P. C. (2025). REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens. The Oncologist. https://doi.org/10.1093/oncolo/oyaf135
Vancouver
Zhong J, Jang A, Abuqayas B, Basu A, Benjamin DJ, Bhatlapenumarthi V, et al. REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens. The Oncologist. 2025. doi:10.1093/oncolo/oyaf135
BibTeX
@article{Zhong2025,
author = {Zhong, Jeffrey and Jang, Albert and Abuqayas, Bashar and Basu, Arnab and Benjamin, David J and Bhatlapenumarthi, Vineel and Bilen, Mehmet Asim and Buch, Dhvani and Chang, Mark and Chin, Erica and Darabi, Sourat and Dhanikonda, Nagendra and Ghatalia, Pooja and Grigg, Claud M and Grier, Abby L and Jindal, Tanya and Jung, Joannah and Kilari, Deepak and Kumar, Hamsa L S and Lee, Suzanna and Neelands, Brittany and Pandya, Chinmayi and Pawalek, Jeff and Staggers, Jaimee and Yildirim, Ahmet and Zakharia, Yousef and Zarrabi, Kevin K and Zimmerman, Michael and Sledge, George and Spetzler, David and Elliott, Andrew and McKay, Rana R and Barata, Pedro C},
title = {REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf135}
}
EUVIMED